Back to Agenda
Session 2 Track C-D: HEOR/Cost Effectiveness Research
Session Chair(s)
Darryl L'Heureux, PhD, MPharm, MSc
Director, Clinical Science, Medical Writing, and Publications
Ambrx, Inc, United States
Recent changes to the reimbursement landscape around the world have elevated the importance of health economics and outcomes research (HEOR) within the pharmaceutical industry. As a result of new demands from payers and population-based decision makers (PBDMs), market access considerations are now seen as integral to drug development from its earliest stages and throughout its life cycle. One example of these changes is the creation of new payment models in the United States that incentivize quality and value rather than quantity of services. In addition to clinical attributes such as safety and efficacy, payers and PBDMs increasingly require evidence supporting the real-world use of a drug, including patient experience, medication adherence, comparative effectiveness, and cost implications. The combination of clinical and real-world attributes represents the value proposition of a new technology. Throughout industry, HEOR is responsible for designing, executing, and disseminating research that provides insight into these questions. The reimbursement dossier is a single document that communicates the value proposition of a new medicine to relevant stakeholders. It is essential for medical communicators working on any HEOR-related work to understand the role of that work within the context of the value proposition. Furthermore, communicators must have a basic understanding of methodologies unique to real-world data generation and economic modeling.
Learning Objective : At the conclusion of this session, participants should be able to:
• Recognize the evolution of HEOR in drug development and changing roles
• Identify value-based components of HEOR
• Apply methodologies relevant to real-world data generation
• Compare different economic evaluations and cost-effectiveness
Speaker(s)
Faculty
Darryl L'Heureux, PhD, MPharm, MSc
Ambrx, Inc, United States
Director, Clinical Science, Medical Writing, and Publications
Faculty
Tom Lang, MA
Tom Lang Communications & Training International, United States
Principal
Faculty
Matthew Monberg
Merck and Company, United States
Director, Outcomes Research
Have an account?